On September 10, 2025, Novo Nordisk announced a company-wide transformation, including a planned reduction of approximately 9,000 global roles by the end of 2026. This significant workforce reduction is aimed at streamlining operations and increasing decision-making speed.
The restructuring is expected to deliver DKK 8 billion in annualized savings, which will be strategically reinvested into core growth areas of diabetes and obesity, including commercial execution and R&D programs. However, these changes are projected to incur DKK 8 billion in one-off costs in Q3 2025.
Consequently, the company revised its full-year 2025 operating profit growth outlook to 4-10% at constant exchange rates (CER), down from the previous 10-16%. This revision primarily reflects the impact of these one-off restructuring costs and signals a more cautious financial outlook for the year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.